Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 17/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396596 | 0.94 | FGFR4 (0.42) | FGFR4FGFR1CDK7CDK9FGFR2 | |
| SCHEMBL4398306 | 0.93 | FGFR4 (0.48) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL4398701 | 0.93 | FGFR4 (0.47) | FGFR4FGFR1CDK7CDK9FGFR2 | |
| SCHEMBL5384979 | 0.92 | FGFR4 (0.45) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL4412853 | 0.90 | FGFR4 (0.56) | FGFR4FGFR1FGFR2FGFR3KIT | |
| SCHEMBL4403368 | 0.90 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL4407678 | 0.88 | FGFR4 (0.51) | FGFR4FGFR1CDK7CDK9FGFR2 | |
| SCHEMBL4404736 | 0.88 | FGFR4 (0.50) | FGFR4FGFR1FGFR2FGFR3KIT | |
| SCHEMBL4409361 | 0.87 | FGFR4 (0.54) | FGFR4FGFR1FGFR2FGFR3KIT | |
| SCHEMBL4398504 | 0.87 | MAPK14 (0.44) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | FGFR4 191/4885FGFR1 88/4885CDK7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.